Results 51 to 60 of about 9,676 (179)

Synthesis and evaluation of non-dimeric HCV NS5A inhibitors [PDF]

Bioorganic & Medicinal Chemistry Letters, 2013
Based on the symmetrical bidentate structure of the NS5A inhibitor BMS-790052, a series of new monodentate molecules were designed. The synthesis of 36 new non-dimeric NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system. Among them compound 5a showed picomolar range activity along with an excellent
Franck, Amblard, Hongwang, Zhang, Longhu, Zhou, Junxing, Shi, Drew R, Bobeck, James H, Nettles, Satish, Chavre, Tamara R, McBrayer, Philip, Tharnish, Tony, Whitaker, Steven J, Coats, Raymond F, Schinazi   +11 more
openaire   +2 more sources

Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region

Юг России: экология, развитие
To research the molecular genetic characteristics of the HCV population circulating among HIV‐infected residents of the Krasnoyarsk Territory, including analysis of resistance‐associated mutations to NS5A inhibitors.
V. E. Ekushov, A. V. Totmenin, L. G. Gotfrid, M. R. Halikov, V.-V. V. Minikhanova, S. E. Skudarnov, T. S. Ostapova, N. M. Gashnikova   +7 more
doaj   +1 more source

GPS2 is required for the association of NS5A with VAP-A and hepatitis C virus replication.

PLoS ONE, 2013
Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) is a component of the replication complex associated with various cellular proteins. It has been reported that G protein pathway suppressor 2 (GPS2) is a potential NS5A-binding factor, as identified
Guodong Xu, Xiu Xin, Congyi Zheng
doaj   +1 more source

Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT To assess the sustained virologic response (SVR12) and safety profile of 12‐week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)‐infected patients across genotypes in Northwest China. This prospective cohort study (2023–2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis ...
Lu Yan, Maimaitijiang Wubuliaishan, Xiaoni Kou, Maimaitiaili Tuerxun, Mingbo Yang, Fanpu Ji, Yingli He, Jiuping Wang, Longdong Zhu, Xiaohong Gao, Fuchun Jing, Xiangchun Ding, Hong Du, Ye Zhang, Hong Jiang   +14 more
wiley   +1 more source

Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes [PDF]

ACS Medicinal Chemistry Letters, 2011
The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign. A more potent analogue, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural ...
Jeffrey L, Romine, Denis R, St Laurent, John E, Leet, Scott W, Martin, Michael H, Serrano-Wu, Fukang, Yang, Min, Gao, Donald R, O'Boyle, Julie A, Lemm, Jin-Hua, Sun, Peter T, Nower, Xiaohua Stella, Huang, Milind S, Deshpande, Nicholas A, Meanwell, Lawrence B, Snyder   +14 more
openaire   +2 more sources

Perilipin 5 alleviates HCV NS5A-induced lipotoxic injuries in liver

Lipids in Health and Disease, 2019
Background The homeostasis of lipid droplets (LDs) plays a crucial role in maintaining the physical metabolic processes in cells, and is regulated by many LD-associated proteins, including perilipin 5 (Plin5) in liver.
Jin Zhang, Xing Gao, Yuan Yuan, Chao Sun, Yuanlin Zhao, Liming Xiao, Ying Yang, Yu Gu, Risheng Yang, Peizhen Hu, Lijun Zhang, Chao Wang, Jing Ye   +12 more
doaj   +1 more source

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. [PDF]

PLoS ONE, 2016
We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus ...
Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi   +22 more
doaj   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

NS5A inhibitors in the treatment of hepatitis C

Journal of Hepatology, 2013
Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation.
openaire   +2 more sources

The NS5A Protein of Hepatitis C Virus Is a Zinc Metalloprotein [PDF]

Journal of Biological Chemistry, 2004
The NS5A protein of hepatitis C virus is believed to be an integral part of the viral replicase. Despite extensive investigation, the role of this protein remains elusive. Only limited biochemical characterization of NS5A has been performed, with most research to date involving the myriad of host proteins and signaling cascades that interact with NS5A.
Timothy L, Tellinghuisen, Joseph, Marcotrigiano, Alexander E, Gorbalenya, Charles M, Rice   +3 more
openaire   +2 more sources